In the healthcare benefit analysis of this cohort of MGMT unmethylated recurrent GBM patients, the majority of ChemoID assay high-response chemotherapies were observed when cells were exposed to regimens containing BCNU, one of the least expensive drugs on the list of those considered. The gene discussed is MGMT; the disease is glioblastoma.